Cargando…

Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough

BACKGROUND: Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [(177)Lu]Lu-HA-DOTATATE uptake in tumors and organs. Therefore, receptor expression status and effects of different (unlabeled) administered peptide amounts during PRRT need to be evaluated. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebinga, Hinke, Veerman, Chayenne H. A. M., de Wit-van der Veen, Linda, Stokkel, Marcel P. M., Hendrikx, Jeroen J. M. A., Aalbersberg, Else A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751249/ https://www.ncbi.nlm.nih.gov/pubmed/36515683 http://dx.doi.org/10.1186/s13550-022-00946-3

Ejemplares similares

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Quality control of [(177)Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
por: Aalbersberg, Else A., et al.
Publicado: (2022)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

Tissue dose estimation after extravasation of (177)Lu-DOTATATE
por: Tylski, Perrine, et al.
Publicado: (2021)

Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [(177)Lu]Lu-DOTATATE
por: Malcolm, Javian C., et al.
Publicado: (2022)

Upregulation of Somatostatin Receptor Type 2 Improves (177)Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
por: Sharma, Rupali, et al.
Publicado: (2023)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
por: Elajami, Mohamad K., et al.
Publicado: (2022)

Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023)

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177)Lu‐PSMA‐617 in prostate cancer patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Lundsten, Sara, et al.
Publicado: (2021)

Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [(177)Lu]Lu-DOTATATE Treatment
por: Hemmingsson, Jens, et al.
Publicado: (2023)

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)
por: Alipour, R., et al.
Publicado: (2023)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy
por: Marin, Gwennaëlle, et al.
Publicado: (2017)

Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
por: Abou Jokh Casas, Estephany, et al.
Publicado: (2020)

Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)

Lutathera(®) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE
por: Urso, Luca, et al.
Publicado: (2023)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2014)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections
por: de Nijs, Robin, et al.
Publicado: (2014)

An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with (177)Lu-DOTATATE for the treatment of neuroblastoma
por: Tesson, Mathias, et al.
Publicado: (2018)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_47625g238o156ups3viu18dmip